NCT06952478 - A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma | Biotech Hunter

Enrollment

486

Participants

Timeline

Start Date

August 12, 2025

Primary Completion Date

November 15, 2027

Study Completion Date

June 25, 2029

Conditions

Refractory or Relapsed Multiple Myeloma

Interventions

BIOLOGICAL

CT-P44(Daratumumab)

CT-P44 1800 mg will be administered as SC injection in combination with Rd until each patient's PD, unacceptable toxicity or Cycle 26, whichever occurs first.

BIOLOGICAL

Darzalex Faspro(Daratumumab)

Darzalex Faspro 1800 mg will be administered as SC injection in combination with Rd until each patient's PD, unacceptable toxicity or Cycle 13, whichever occurs first.

Trial Locations (1)

11217

RECRUITING

Taipei Veterans General Hospital, Taipei